Massachusetts Financial Services Co. MA Raises Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

Massachusetts Financial Services Co. MA grew its position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 5.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,711,015 shares of the biotechnology company's stock after purchasing an additional 93,185 shares during the period. Massachusetts Financial Services Co. MA owned 2.94% of Ascendis Pharma A/S worth $233,348,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Gilbert & Cook Inc. grew its stake in Ascendis Pharma A/S by 8.4% in the 4th quarter. Gilbert & Cook Inc. now owns 2,838 shares of the biotechnology company's stock worth $357,000 after acquiring an additional 220 shares during the period. Quadrant Capital Group LLC grew its position in shares of Ascendis Pharma A/S by 90.4% in the fourth quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company's stock valued at $40,000 after purchasing an additional 151 shares during the period. PNC Financial Services Group Inc. increased its stake in Ascendis Pharma A/S by 1.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 16,384 shares of the biotechnology company's stock valued at $2,064,000 after purchasing an additional 159 shares during the last quarter. Trexquant Investment LP purchased a new position in Ascendis Pharma A/S during the fourth quarter worth about $1,243,000. Finally, EverSource Wealth Advisors LLC boosted its stake in Ascendis Pharma A/S by 37.6% in the 4th quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company's stock worth $42,000 after buying an additional 91 shares during the last quarter.

Analyst Ratings Changes

ASND has been the subject of a number of research analyst reports. Evercore ISI upped their price objective on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an "outperform" rating in a research note on Tuesday. The Goldman Sachs Group boosted their target price on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the company a "buy" rating in a report on Tuesday. TD Cowen cut their price target on shares of Ascendis Pharma A/S from $175.00 to $157.00 and set a "buy" rating on the stock in a research note on Wednesday, September 4th. Oppenheimer reiterated an "outperform" rating and issued a $190.00 price target (up previously from $180.00) on shares of Ascendis Pharma A/S in a report on Tuesday. Finally, Citigroup upped their price objective on Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a "buy" rating in a report on Tuesday. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $193.77.

Ascendis Pharma A/S Price Performance

Ascendis Pharma A/S stock traded up $2.29 during midday trading on Wednesday, hitting $148.88. 885,098 shares of the company were exchanged, compared to its average volume of 438,193. The company has a market cap of $8.67 billion, a PE ratio of -15.22 and a beta of 0.63. Ascendis Pharma A/S has a fifty-two week low of $85.29 and a fifty-two week high of $161.00. The company's fifty day moving average price is $132.71 and its 200-day moving average price is $136.43.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.